NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.

We recently published an article titled Why These 10 Dividend Stocks Are Declining? In this article, we are going to take a ...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key ...

Welireg generated $139 million in sales during 2024’s third quarter and is the only approved HIF-2α inhibitor in the U.S. Merck’s application in PPGL is based on objective response rate and ...